Jing T. Tan
Hong Kong, HCW, Hong Kong Special Administrative Region
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort study.
Journal: Gut
Published: May 09, 2025
Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: November 30, 2024
Effects of Successful Versus Delayed/Failed Helicobacter pylori Eradication Therapy on Subsequent Fracture Risk: a Population-Based Cohort Study.
Journal: Journal of gastroenterology and hepatology
Published: September 24, 2024
Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.
Journal: Helicobacter
Published: July 05, 2024
Effect of metabolic dysfunction-associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant.
Journal: Journal of gastroenterology and hepatology
Published: April 29, 2024
Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
Journal: Hepatology (Baltimore, Md.)
Published: December 04, 2023
Relationship between Helicobacter pylori infection, osteoporosis, and fracture.
Journal: Journal of gastroenterology and hepatology
Published: November 03, 2023
Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients.
Journal: Vaccines
Published: January 13, 2023
Showing 1-9 of 9
Last Updated: 09/26/2026